0B68 Schilder, Russell - Thomas Jefferson University - Thomas Jefferson University
Dr. Schilder

Russell Schilder, MD

Contact Dr. Schilder

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion
  2. Refractory fallopian tube carcinoma - Current perspectives in pathogenesis and management
  3. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer
  4. Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer
  5. A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study
  6. Influence of bevacizumab on vaginal cuff evisceration eight months after ovarian cancer cytoreduction surgery: A case report
  7. Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary
  8. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study
  9. A phase i trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study
  10. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study
  11. Epithelial-to-mesenchymal transition and cellular membrane receptors in ovarian cancer: Moving forward in the era of molecularly targeted therapy
  12. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study
  13. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary
  14. A Phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix
  15. Management of Recurrent Ovarian Carcinoma: Current Status and Future Directions
  16. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash
  17. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies
  18. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study
  19. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
  20. Platinum resistance: The role of DNA repair pathways
0